MassChallenge

Extracellular specializes in research and development platforms and biomanufacturing solutions aimed at enhancing the sustainable biotech ecosystem. The company leverages its expertise in cellular behavior and scale-up processes to efficiently produce biomass for cultivated meat and seafood, as well as for applications in plant cell culture, bio-cosmetics, bio-supplements, and bio-materials. By digitalizing process development and aggregating extensive data, Extracellular facilitates improved decision-making and accelerates the commercialization of biotech innovations. The focus is on reducing research and development costs and timelines, enabling sustainable biotech companies to bring their products to market more rapidly through efficient and cost-effective cellular agriculture practices at scale.

Sonali Bioplastics solves the plastic pollution problem with plant based alternatives that reduces carbon emissions. Sonali Bioplastics takes a sustainable development approach toward solving plastic problems and promote eco-friendly farming. The company was founded in 2019 and is based in San Jose, California.

Producer of food products intended to provide fish meat alternatives through cell cultivation. The company specializes in producing cultivated cell-based fish fat to greatly enhance the flavor, texture aroma and nutrition of alternative protein products, enabling consumers to get healthy fats such as omega-3 that protect from heart diseases.

Yeastime is a pioneering company focused on transforming the fermentation process through its innovative ultrasound technology. This deep-tech hardware device optimizes fermentation by utilizing sensors and mechanical waves, resulting in a reduction of time, costs, and environmental impact. By accelerating fermentation by up to 30%, Yeastime enhances industrial productivity while simultaneously minimizing the ecological footprint of its clients. This groundbreaking approach positions Yeastime as a leader in food technology, offering significant advancements in efficiency and sustainability.

CNS Therapy, they contribute to human well-being through mind-body therapy and the research, design, education, and sale of devices that alleviate chronic disease, restore health, and extend useful life. They are a spin off from the University of North Carolina (UNC). Their base technology is a patent pending approach to chronic pain which combines operant behavioral therapy with a proprietary device which enhances learning and resets the autonomic nervous system - called SET - Systolic Extinction Training. They are dedicated to providing long lasting pain relief to patients. Their unique combination of psychological training and electrostimulation helps chronic pain patients to starkly reduce or even eliminate their pain and allow them to return to their daily lives.

Sóliome is a biotechnology company founded in 2021 and based in San Francisco, California. The company specializes in developing protein-based sunscreens designed to be safe for both the skin and the environment. These innovative products aim to reduce inflammation and skin damage caused by traditional sunscreens, which often contain harmful xenobiotic ingredients that can absorb into the skin and contribute to ecological harm. Sóliome's approach allows customers to protect their skin from harmful rays without the adverse effects associated with conventional sunscreen formulations.

Umami is a pioneering agri-tech company that specializes in cultivating microgreens using advanced, indoor vertical farming techniques. It offers a diverse range of microgreen products, including radish, mustard, red clover, and specialty mixes, along with value-added items like umami pesto and mayonnaise. Umami's mission is to produce pure, great-tasting food at affordable prices, making it a leading supplier in the microgreens market.

Econutri is a company focused on sustainable protein production through the recycling of CO₂. Utilizing advanced bio-processing technology, it transforms carbon dioxide into high-quality proteins that serve a variety of markets, including livestock feed, pet food, non-food products, and human food options. By providing eco-friendly and nutritious protein alternatives, Econutri aims to make a positive environmental impact while helping to reduce the global carbon footprint.

Updairy is a company that produces food ingredients, specifically animal-free dairy proteins. It uses microorganisms to create these proteins, mimicking the taste and nutrition of traditional dairy products but with significantly reduced greenhouse gas emissions. This allows customers to develop new dairy products with a lower environmental impact than traditional dairy farming.

SCALE Advanced Biocomposites specializes in the development of natural-fiber composites aimed at advancing the use of bio-based materials across various industries, including sporting goods, automotive, wind power, and aerospace. The company's innovative materials and technologies offer an effective alternative to carbon fiber, enhancing performance while simultaneously reducing costs and greenhouse gas emissions. This approach supports clients in their efforts to decarbonize high-performance composites, contributing to a more sustainable built environment. Through its focus on creating new, bio-based materials, SCALE seeks to significantly lower emissions and promote the adoption of eco-friendly solutions in multiple sectors.

Organic Fields offers an innovative biological, certified organic fertilizing solution to commercial growers in the agricultural.

Nature's Principle, originating from a Ph.D. project at Delft University of Technology in the Netherlands, specializes in a patented mixed culture fermentation technology that aims to revolutionize traditional agro-chemical production methods. This innovative process effectively converts low-value waste streams, including sugar beet, pulp, and molasses, into valuable products such as lactic acid and poly-lactic acid, which can be utilized in food preservation and bioplastics. By leveraging natural principles to cultivate microorganisms, the company enhances their productivity without resorting to genetic engineering. This approach allows clients to replace oil-based chemicals, offering significant advantages in water consumption, carbon dioxide emissions, and land usage, thereby promoting more sustainable production practices.

Fotortec is a biotechnology company focused on sustainable protein production. It specializes in producing mushroom-based ingredients that leverage technology to convert various types of vegetable waste into fully traceable plant-based products. This innovative approach aims to provide consumers with adequate nutrition while promoting environmental sustainability. Through its processes, Fotortec contributes to reducing food waste and enhancing the availability of nutritious food options.

Embryoxite is a biotechnology company specializing in non-invasive diagnostic services for pre-implantation embryos in human-assisted reproduction. It operates a platform that combines artificial intelligence, metabolomics, embryo imaging, and clinical data to enhance embryo selection accuracy, thereby improving patient outcomes in fertility treatments.

Restoring crops' ability to defend against pests.

Xibus Systems, Inc. is a biotechnology company based in Somerville, Massachusetts, specializing in the development of microbiological analytics and testing tools. The company focuses on creating solutions that detect pathogens, allergens, and spoilage organisms in consumable products. By integrating materials science, biotechnology, and optics, Xibus Systems aims to provide quantitative and array-based testing capabilities that are both efficient and cost-effective. Their innovative technology is designed for high throughput and rapid results, while also featuring a roadmap for compact and handheld hardware options. This unique combination of proprietary materials and biological agents positions Xibus Systems to effectively address the growing demands for food safety and quality assurance in the market.

SeaStock is a global marine research company focused on developing solutions for the production and extraction of compounds derived from seaweed and algae. The company specializes in the cultivation and processing of asparagopsis seaweed, which is utilized in methane-reducing feed ingredients. By offering a range of products, SeaStock enables clients to select the specific solutions that meet their needs. Through its innovative approach, the company aims to contribute to sustainable practices in marine science and agriculture.

BioMixing is a biotechnology company specializing in the development and operation of advanced agitation systems for bio-fermentation processes. It focuses on applying fluid dynamics principles to reduce cell damage and optimize mixing in bioreactors, thereby enhancing the efficiency of fermenters and bioreactors for various biotechnological applications.

LiveGrow Bio is a biotechnology company specializing in microbial fermentation and formulation. It has developed a patented technology that significantly reduces the production cost of biopesticides and biostimulants by up to 95%, while also extending their shelf life to over two years at room temperature. This innovation facilitates the commercialization of biological products, making them viable solutions for a wide range of crops, beyond just high-value organic ones. LiveGrow's technology allows for the modular production of any microbe as a biostimulant or biopesticide, utilizing a unique manufacturing method that grows microbes directly inside retail packaging sold to farmers. This approach eliminates the need for traditional large-scale fermentation facilities and the associated processing steps, enhancing scalability and efficiency in the agriculture sector.

Astron Medtech is a medical technology company focused on improving patient outcomes in tendon repair. The company develops disposable minimally invasive surgical devices that significantly reduce recovery time from six months to four months. By utilizing less invasive and sustainable surgical techniques, Astron Medtech aims to enhance the efficiency of surgical services while providing better options for patients undergoing tendon repair procedures.

Azul Bio specializes in marine ecosystem preservation and restoration, focusing on enhancing the resilience of coral reefs against climate change. The company provides biological analysis services, including DNA-based biodiversity assessments, species genotyping, microbiome profiling, and disease detection, to support marine research, aquaculture, and environmental monitoring.

Dart Biosciences works in the healthcare industry. It creates tailored gene therapies for a variety of uncommon and prevalent disorders.

Electronrx specializes in personalized digital medicine, focusing on innovative solutions for chronic disease management and hospital patient care. The company has developed a predictive healthcare and diagnostics platform that monitors cardiovascular health remotely. This platform utilizes advanced technologies, including biomedical engineering, data science, and machine learning, to sense the physiological environment and deliver tailored therapeutic interventions. By enabling clinical professionals to provide targeted treatments through short waveforms of current and voltage, Electronrx empowers patients to self-monitor their health and effectively manage conditions such as period pain during treatment.

Form Biologics is a new platform technology for the injectable formulation of biologic medicines in order to make treatments more patient-friendly and efficacious.

Skygenic is a cloud-based software platform designed to facilitate the storage and analysis of genomic data, thereby enhancing the research capabilities of scientists. Developed in collaboration with experts from Harvard Medical School and Boston Children's Hospital, the platform aims to simplify the data analysis process for non-programming scientists, enabling them to independently analyze and interpret biological data. By addressing the challenges faced in early-stage and translational research, Skygenic effectively reduces the reliance on bioinformaticians, allowing research to progress more efficiently and economically. This innovation supports academic institutions, hospitals, biotechnology, and pharmaceutical organizations by streamlining workflows and enabling researchers to focus on critical aspects of their work, ultimately accelerating scientific discovery.

Symphony Biosciences is focused on developing innovative cancer therapies aimed at improving treatments for solid tumors, particularly targeting triple-negative breast cancer. This type of cancer currently has limited effective treatment options, primarily relying on toxic chemotherapies that often fail to provide significant survival benefits. By utilizing biomaterials in its research, Symphony Biosciences aims to enhance the immune response against these challenging cancers, ultimately providing healthcare professionals with better tools to treat patients. The company's mission is to improve patient access to effective cancer treatments and address the critical needs within oncology.

Speratum is a biopharmaceutical company focused on microRNA-directed oncology therapies. The Company was founded in 2014 by Christian Marín-Müller, Ph.D. and is dedicated to the development of a patented treatment for pancreatic cancer based on the combination of tumor suppressive microRNA molecules and nanoparticle-based drug delivery technologies. The Company is currently entering the final stage of preclinical trials for the pancreatic cancer therapy, while simultaneously expanding the patent’s coverage to incorporate other types of cancer and non-cancer indications and illnesses and expanding its intellectual property (IP) portfolio with complementary technologies in the fields of nanotechnology, medical devices and veterinary medicine.

Arnav Biotech is a biotechnology company that operates as a Contract Development and Manufacturing Organization (CDMO), specializing in mRNA technology. It offers services for the design, development, and manufacturing of custom and cataloged mRNA products, supporting research, therapeutics, and vaccines. By providing these services, Arnav Biotech enables researchers to concentrate on their specific areas of interest, thereby democratizing access to mRNA-based life sciences.

KardioStatus is a healthcare technology company that converts biometric data into personalized clinical treatments. Its platform, developed by leading physicians and engineers, creates unique biometric profiles for patients and provides tailored therapeutic recommendations, helping healthcare providers enhance patient outcomes, lower costs, and simplify decision-making processes.

YouthBio Therapeutics Inc. is a biotechnology company dedicated to developing rejuvenation gene therapies through the innovative application of partial reprogramming techniques. By leveraging the principles of cellular reprogramming, the company aims to restore a youthful gene expression profile in specific cells. This approach seeks to produce beneficial therapeutic effects in targeted organs, enabling the prevention of age-related diseases and potentially delaying or reversing the aging process. Through its research and development efforts, YouthBio Therapeutics aspires to contribute significantly to the field of longevity and improve health outcomes for aging populations.

Intek Scientific develops multiplexed immunofluorescence imaging technology.This will empower clinicians and researchers to gain a deeper understanding of cancer and provide effective and customized therapeutic strategies to tackle even the most challenging cancers.

ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

Trove Health offers a platform designed to enhance access to patient data for patients, healthcare providers, and life sciences organizations. The company's primary focus is on clinical trial recruitment, where it aims to build a diverse and engaged database of consented participants. By efficiently identifying and recruiting patients who meet specific enrollment criteria across various geographies and therapeutic areas, Trove Health enables researchers to advance medical cures and therapies. Additionally, the platform empowers patients by allowing them to control and potentially monetize their health information while receiving tailored treatments.

Drizzle Health develops low-cost, high-performance tuberculosis and other bacterial disease diagnostics.

Lura Health has developed a groundbreaking non-invasive health monitoring platform that utilizes saliva as a diagnostic fluid, aiming to enhance clinical outcomes in chronic disease management. Founded in 2017 and based in Cambridge, Massachusetts, the company targets various chronic disease markets, including heart disease, chronic kidney disease, diabetes, and tooth decay. Its innovative sensors are integrated into patient-friendly orthodontic devices such as removable retainers and fixed braces. These sensors continuously measure analytes in saliva and automatically transmit data to a smartphone application, allowing users to track key diagnostic metrics related to their oral health. By enabling individuals to monitor their health in real-time, Lura Health seeks to improve personal health management and empower users to take charge of their well-being.

Cellorama multipurpose devices, reagents, and processes are patent-pending and protect cell structure and integrity during many procedures. User-friendly and cost-effective devices are designed to minimize stressful stages in the laboratory while saving time and vital resources.

Earnest Agriculture collaborates with farmers to transform agricultural waste into innovative biofertilizers that enhance crop yields. By converting waste products such as manure and vegetable remnants, the company provides an eco-friendly solution that not only helps farmers manage their waste but also offers them a potential source of additional income. Utilizing a combination of composting, vermicomposting, and advanced microbial technologies, Earnest Agriculture develops proprietary fertilizers designed to improve soil quality, promote drought resistance, and suppress pathogens. This approach not only reduces the environmental impact of farming but also allows farmers to lower their input costs while increasing their productivity.

PlusVitech is a company dedicated to developing effective and safe therapeutic treatments and complementary diagnostic tests for cancer patients. It specializes in non-invasive genetic cancer detection, utilizing small molecules and monoclonal antibodies as alternatives to traditional tissue biopsies. This approach allows for earlier detection and treatment of cancers, thereby improving patient outcomes while minimizing discomfort and the time associated with invasive procedures.

Stellate Therapeutics is a private biotechnology company specializing in the development of small molecules derived from human gut bacteria to create personalized therapies for neurological diseases. The company focuses on addressing age-related neurological conditions, particularly through its research on the gut-brain axis. Stellate has developed a portfolio of drug candidates, including AMA-101, which aims to be a first-in-class therapy for Parkinson's disease. Through its microbiome-derived medicine platform, Stellate Therapeutics is engaged in comprehensive research and has established capabilities in discovery, screening, production, and diagnostic development, striving to provide effective treatments for neurological disorders.

Women aged 20-45 cannot get screened for breast cancer because existing solutions are unreliable. However, 81% want to. At The Blue Box, we have built a pain-free, low-cost, sensitive, radiation-free device to detect breast cancer in urine with a sensitivity of 83%. In 2024, we’ll launch into the market, bringing The Blue Box to private gynecology clinics with a Diagnostics-as-a-Service subscription model, and a pay-per-test revenue stream that we’ll share with doctors.

Azooka is a biotechnology company focused on manufacturing proprietary fluorophores and molecular biology products for life science research and molecular diagnostics. The company produces a range of fluorescent dyes and tags for applications involving DNA, RNA, chromosomes, and live cells, as well as molecular-grade sample collection and transport mediums. Azooka aims to provide secure and sustainable biotech consumables at affordable prices, making these essential tools accessible to researchers worldwide. Recently, the company was recognized as the "Best Women-Led Enterprise," highlighting its commitment to innovation and leadership in the biotech sector.

Narval is a biotechnology company specializing in the development of synthetic antibody mimetic proteins (AMPs). These AMPs are significantly smaller than conventional antibodies, yet retain their biological functionality. They offer several advantages, including the ability to penetrate tissue barriers, generate limited immune reactions, target small and hard-to-reach antigens, and withstand heat. Narval's technology enables the creation of novel first-in-class immunotherapeutic drugs for diseases previously challenging to treat with monoclonal antibodies, such as respiratory, eye, and autoimmune conditions. The company leverages machine learning and artificial intelligence to optimize its drug development capabilities.

Auspex Diagnostics is an AI startup focused on enhancing cancer care through advanced diagnostic services. It utilizes machine learning algorithms to analyze the genomic information from patients' tumor samples. This analysis helps in accurately assessing the risk of cancer recurrence and the efficacy of various treatments. By providing valuable insights, Auspex Diagnostics enables oncologists and patients to make informed, data-driven decisions regarding personalized treatment plans, ultimately aiming to improve the overall quality of cancer care.

Anviron is a company focused on developing advanced therapies for late-stage cancers. It employs a team of scientists, doctors, and clinicians who work collaboratively to address the challenges posed by difficult-to-treat cancers. By leveraging cutting-edge scientific research, Anviron aims to create innovative therapies that meet the unmet medical needs in oncology. The company's efforts are directed towards improving patient outcomes and transforming the landscape of cancer care.

Cultimate Foods is a cellular agriculture company focused on developing cultivated fat for hybrid alt-meat products. By replicating the structure of animal fat tissue, the company aims to create plant-based fat alternatives that enhance the sensory experience of meat consumption. Utilizing a unique technological approach to 3D cultivation, Cultimate efficiently produces its ingredients while reducing production costs. The company’s innovative methods enable the development of cell-cultured meat alternatives that provide a sustainable and ethical option for consumers seeking to enjoy meat without compromising on taste or texture.

Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.

myBiometry is developing a platform to monitor/manage patients with chronic disease using biomarker data from proprietary sensors and ML to identify patients at risk of treatment failure. Our initial focus is asthma where treatment failure occurs over 46% of the time (11.5M US patients, $80 billion). We are developing a single use, disposable sensor and device to track a biomarker of inflammation in breath. The data determines changes in adherence, treatment response, and risk of attack.

miniMarrow presents a new disruptive therapeutic approach for the in-situ production of blood components in leukemic patients to replace weekly and burdensome transfusions markedly increasing patient quality-of-life. miniMarrow is operating in stealth mode. miniMarrow was established in Renens, Vaud

Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.

Ostiio is focused on developing an innovative bone distraction system aimed at correcting skeletal deformities and deficiencies. The company has created a fully implantable device that is buried beneath the patient's skin, eliminating the need for external components. This advanced system features a magnetically driven distraction mechanism that can be expanded with precision and monitored remotely by physicians. This programmability provides surgeons with enhanced transparency and control during the treatment process, addressing a longstanding challenge in skeletal correction. Ostiio operates as a company under the Penn Center for Innovation, emphasizing its commitment to advancing medical technology in orthopedics.

INIA Biosciences focuses on creating non-invasive medical devices that leverage sound wave technology to manage chronic inflammatory diseases. The company's innovative system combines biomarker monitoring with an ultrasound stimulator, aimed at reducing inflammation associated with transplant rejection and decreasing reliance on immunosuppressant medications. This home-administered, closed-loop monitoring system provides physicians with advanced diagnostic capabilities to improve the treatment and prevention of organ failure, ultimately enhancing patient care in chronic disease management.

BioBQ is a cultivated meat company focused on producing slaughter-free beef brisket and other BBQ meats from cultured animal cells. Utilizing proprietary technologies, the company efficiently creates whole cuts of meat in weeks, significantly reducing the time compared to traditional cattle farming. This innovative approach not only allows for precise control of meat content and flavor but also minimizes the environmental impact associated with conventional meat production. By offering a sustainable alternative, BioBQ aims to meet the growing consumer demand for tasty and environmentally friendly meat options, ensuring that animal welfare and climate concerns are addressed.

Advanced Microfluidics, based in Ecublens, Switzerland, is a machinery manufacturing company that specializes in developing and producing high-end lab equipment components. Their primary focus is on automated liquid handling systems, which are designed to minimize cross-contamination and reduce internal volume, ensuring precise and efficient fluidic performance. The company's products cater to both laboratory and industrial sectors, providing solutions with no dead volumes.

Ronawk is a biotechnology company that specializes in the development of T-Block technology, which produces patient-specific biologics for the treatment of diseases, including cancer, organ injuries, and burns. The company has created a proprietary method for growing primary stem cells in a three-dimensional environment, allowing these cells to retain their essential characteristics outside the body. This innovative approach enables the rapid expansion of stem cells, making them suitable for early-stage diagnostics and the repair of injured tissues. Additionally, Ronawk focuses on preserving primary cells from patients for future use in reconstructive surgeries, thereby enhancing the efficiency and density of human cell growth for tissue generation and disease modeling.

MyoGene Bio focuses on creating innovative therapies for muscle diseases, with an initial emphasis on a gene-editing treatment for Duchenne muscular dystrophy. The company leverages advanced technologies to directly address the underlying causes of this condition, aiming to significantly improve disease progression. By targeting the fundamental issues associated with Duchenne muscular dystrophy, MyoGene Bio seeks to provide clinicians and patients with effective solutions that can lead to meaningful advancements in managing severe muscle disorders.

Selmod, based in Basel, Switzerland, specializes in developing innovative therapies aimed at treating life-threatening, multi-drug resistant infections. The company focuses on discovering and advancing small molecules and peptides that target new mechanisms of action, addressing the urgent need for effective treatments in hospital settings where first-line therapies have failed. Selmod aims to provide second-line and last-resort options through a disruptive approach that incorporates dual modes of action to overcome resistance mechanisms. The company's lead candidates, SLM500, SLM100, and SLM300, have shown promise in preclinical studies, with market projections indicating a total available market exceeding $9 billion. With an experienced leadership team skilled in advancing clinical candidates for major pharmaceutical companies, Selmod plans to utilize funding to advance three IND-enabling candidates and six lead-optimized candidates into proof-of-concept stages.

Condor Software specializes in clinical finance software designed to enhance financial decision-making in the pharmaceutical and biotech sectors. By integrating real-time clinical trial data and facilitating collaboration with third-party vendors, the company enables more accurate accounting and financial planning for clinical programs. Its software promotes operational efficiency by streamlining workflows and reducing the time spent on cash flow management. The focus is on optimizing financial resources to accelerate the development of innovative treatments, thus supporting companies in making informed business decisions that drive impactful outcomes.

Algdeha specializes in sustainable biotechnology solutions aimed at industries reliant on fish-based products. The company focuses on developing innovative methods for large-scale algae production, utilizing natural resources such as wave energy, sunlight, and ambient heat to minimize costs. By providing an alternative to traditional animal feed derived from fish, Algdeha's approach supports sustainability and reduces the environmental impact associated with fish dependency in animal agriculture.

Netnoids Rx Laboratories operates a cancer contract research organization that uses patient-derived organoid model systems to help find a cure for rare cancers.

Galileo Innovations develops human performance-optimizing biotech gear and equipment for athletes, first responders, military members, and labor industry workers. Its proposed technology, KordoFan, augments users with actionable insights concerning environmental and biometric hazards in real-time to target heat injuries; through an array of biomimicry cooling designs, the device aids in speed, agility, mental clarity, muscle recovery, strength, and stamina during training/shifts.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

GreenBTS specializes in developing high-technology and sustainable products aimed at enhancing agricultural efficiency and environmental responsibility. The company manufactures organic biofertilizers and biopesticides designed to improve urban farming, plant care, and food production. These products protect crops from pests and diseases while offering specially formulated nutrients tailored to various crop types, which contribute to better growth and quality. By focusing on innovative and eco-friendly solutions, GreenBTS enables farmers to safeguard their crops until harvest, promoting a more sustainable approach to agriculture.

We create healthy and sustainable solutions for the world based on insects. A very nutritive and eco friendly food source. Currently we are using about 50% of the habitable land for agriculture and the livestock industry is the major contributor to CO2 emisions, but In just 30 years the amount of food available will not be enough for the world`s population. By making healthy, and tasty products from insect powder such as flour for bread, cake mix, and even protein shakes, we are able to reduce the amount of livestock usage and also provide a sustainable and scalable solution. Our business model is based on 3 keypoints: >Mass and Standarized Production which is possible using our insect incubator (which is patent pending) >Sustainable and efficient Production since Costa Rica has the perfect weather conditions, >And our Partner Program to provide jobs and income to the poorest sectors of Costa Rican society. Our partner program is supported by BID Lab and Fundecooperación who are helping us deliver the program on a national scale. Costa Rica Insect Company and we Save the World Eating Bugs!

LIALT Laboratorio de Investigación Alternativa develops toxicological evaluations without the use of animals. LIALT replaces the use of animals through the use of three-dimensional tissues in conjunction with internationally recognized protocols that provide more specific information on the mechanisms of toxic action than that obtained in animals, offering a solution to the problem previously exposed.

Labinnova detects Breast Cancer in a Breath Sample with 98% sensibility. providing Qualitative results.

Uniphage is a biotechnology company that specializes in developing innovative solutions to combat bacterial infections, with a focus on agriculture. It combines the power of bacteriophages, naturally occurring viruses that infect bacteria, with artificial intelligence to create precise and safe antimicrobial products. Uniphage's primary goal is to reduce the use of harmful fungicides, bactericides, and antibiotics in plant agriculture by providing more efficient and eco-friendly alternatives. By using AI algorithms to predict the effectiveness of bacteriophages against specific bacterial infections, Uniphage aims to accelerate the development of new pesticides, thereby minimizing risks to human health and the environment.

NurLabs develops label-free and reagent-free diagnostics to detect cancer early when it is most treatable.

Lepidext specializes in managing populations of Lepidoptera pests through the development of species-specific bio-pesticides. Founded in 2015 by Angelika Fath-Goodin and Bruce Webb in Lexington, Kentucky, the company aims to enhance crop security and promote agricultural prosperity. By leveraging a deep understanding of insect biology alongside farmers' expertise, Lepidext provides safe and effective pest control solutions that reduce reliance on genetically modified plants and chemical pesticides. Their technology specifically targets the corn earworm and other harmful insects, offering an innovative approach to pest management that is user-friendly and environmentally responsible.

Therapeutic Vision focuses on the development of pharmaceuticals primarily for the companion animal market and eventually their owners.

AcousticaBio is focused on transforming intravenous medications into formulations suitable for subcutaneous injection. The company has developed a fluid processing technology that creates complex microparticles necessary for these subcutaneous formulations. This innovative approach allows for the conversion of intravenously delivered biologic products into highly concentrated, small-volume injections. By enabling patients to self-administer life-saving drugs with reduced pain and discomfort, AcousticaBio aims to streamline treatment processes, minimizing the need for lengthy hospital visits and enhancing patient convenience.

Organic Robotics Corporation, founded in 2018 and based in Rochester, New York, specializes in the design and development of advanced sensors that measure touch in real time. The company's flagship product, Light Lace, utilizes fiber-optic technology to create a flexible sensor capable of bending and twisting with the human body, offering effective motion capture and pressure sensing. This innovative solution combines sensibility, elasticity, and washability at a competitive cost. Additionally, Organic Robotics focuses on performance monitoring for professional athletes, providing real-time feedback on motion, muscle fatigue, and vital signs. Their technology is designed for comfort and minimal distraction, enabling accurate analysis of chest movement to deliver actionable insights regarding fatigue and performance levels.

Glamorous AI develops an artificial intelligence-based drug discovery platform that focuses on low-data scenarios in pharmaceutical research. The platform utilizes AI to identify and optimize novel chemical compounds, facilitating the discovery of new medicines by analyzing prior experimental results. It is designed to handle sparse, noisy, and small datasets, making it particularly effective for tackling complex drug discovery challenges. By leveraging a large repository of pre-trained and customizable AI models, Glamorous AI enables researchers to screen extensive chemical libraries and address novel and first-in-class therapeutic targets, ultimately driving innovation in drug development and contributing to the advancement of treatments for various diseases.

BioSens8 is a developer of advanced biosensors designed to enhance health monitoring and prevent chronic diseases. The company's innovative platform offers real-time, quantitative biosensors that serve various applications. In healthcare, these biosensors assist women in assessing their fertility health, providing crucial information for family planning. In agriculture, BioSens8's technology enables farmers to manage herds effectively and optimize animal reproduction. Additionally, the biosensors can evaluate environmental health, contributing to the revitalization of fragile ecosystems. By catering to the healthcare, agriculture, military, and biomanufacturing sectors, BioSens8 aims to provide efficient solutions for holistic health monitoring.

Gensor develops a virus testing platform based on the gene field-effect transistor technology.

Stemloop is a biotechnology company focused on developing innovative cell-free biosensing products that enhance chemical and molecular testing processes. By utilizing genetically encoded sensing and response mechanisms, Stemloop creates accessible and actionable biosensors that are faster, cheaper, and easier to use than traditional laboratory tests. The company's mission is to address unmet needs in chemical sensing and detection, enabling medical professionals to deliver accurate and timely test results at reduced costs. Through its novel technology, Stemloop aims to unlock the potential of biology to respond effectively to various global challenges.

Akttyva Therapeutics specializes in the development of targeted therapeutics aimed at addressing cell barrier dysfunction associated with various vascular disorders. The company leverages a deep understanding of biological pathways, along with advanced artificial intelligence and machine learning techniques, to design solutions that enhance the treatment of these conditions. Through its innovative approach, Akttyva Therapeutics seeks to provide healthcare professionals with effective tools to manage and treat disorders related to cell barriers.

Transcera is a biotechnology company focused on advancing the treatment of chronic diseases through innovative drug delivery systems. It has developed a novel lipid-based platform that enhances the targeting and absorption of therapeutic molecules, allowing larger drugs to effectively cross cellular barriers. This approach aims to improve the pharmacokinetics of treatments, ultimately benefiting patient outcomes by ensuring that medications are delivered more precisely and efficiently. Transcera's technology represents a significant advancement in drug delivery, addressing critical challenges in the management of chronic conditions.

Diamante is an Italian company founded in 2016 and headquartered in Verona, specializing in the development and manufacture of diagnostic devices for autoimmune diseases using advanced nanomaterials. The company utilizes plants as bioreactors to produce nanoparticles derived from modified plant viruses. This innovative approach facilitates the creation of new diagnostic tools and therapies aimed at addressing autoimmune diseases, particularly through techniques that involve the re-induction of these conditions. By leveraging plant-based nanotechnologies, Diamante is positioned to contribute significantly to advancements in autoimmune disease diagnosis and treatment.

Leucine Rich Bio is India's first and only company focused on microbiome-based genomics. It operates a genomics platform that analyzes the human microbiome, often referred to as the "Second Genome," to enhance understanding of its impact on health and wellness. The company offers a three-phase customized approach that includes nutritional recommendations and personalized supplements tailored to individual intestinal microflora. Its applications span various medical fields, including gastroenterology, endocrinology, oncology, mental health, and reproductive health, aiming to provide clinical solutions that promote overall human health. As interest in the microbiome continues to grow among researchers, clinicians, and consumers, Leucine Rich Bio is positioned at the forefront of this emerging area of precision medicine.

FairFlavor develops nutritious vegan alternative dairy food made of a super nut from Indonesia using a patented fermentation technology

Fybraworks Foods, Inc. is a food biotechnology company founded in 2020 and based in Minnetonka, Minnesota. It specializes in developing alternative meat substitutes and animal-free meat structural proteins through advanced fermentation techniques. The company aims to replicate the taste and texture of traditional meat while promoting sustainability and humane practices. By providing innovative technological solutions, Fybraworks Foods enables industry leaders and consumers to access meat alternatives that minimize animal slaughter and reduce greenhouse gas emissions, thereby contributing to environmental preservation.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

Sophie's BioNutrients is focused on creating sustainable plant-based protein derived from microalgae through advanced fermentation technologies. The company specializes in optimizing strains, precision fermentation, and protein extraction to produce a high-purity protein powder. This innovative product offers various functionalities, catering to the food industry, particularly for the development of imitation seafood products. By leveraging fermentation methods, Sophie's BioNutrients aims to enhance the availability of alternative protein sources while promoting sustainability in food production.

React4life is an Italian biotech company established in 2016 by Silvia Scaglione and Maurizio Aiello, following over 15 years of research and development. The company focuses on advancing biomedical research through its innovative technology, MIVO® (Multi In Vitro Organ), which represents a next-generation organ-on-a-chip system. This microphysiological platform allows researchers to simulate human biology more accurately in laboratory settings, addressing the limitations of traditional in vitro assays and animal testing. React4life's technology enhances the reliability and predictivity of various applications, including pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals. By enabling the cultivation of three-dimensional human-like tissues for in vitro testing, React4life aims to improve the effectiveness of laboratory experiments and promote ethical research practices.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015. It specializes in the research and development of a medical device designed for blood type analysis and the detection of infectious diseases. The company's flagship product offers rapid and accurate testing for various conditions, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. This portable device operates independently of electricity or laboratory infrastructure, making it accessible for use in diverse environments. Additionally, Criam's technology is scalable, allowing a single reader to perform multiple tests using specific cartridges and advanced computer vision algorithms. By optimizing blood testing services, Criam aims to provide timely health information and improve clinical decision-making.

Microbe Plus specializes in the development of innovative microbiological bio-products aimed at enhancing plant growth and protection. The company manufactures multi-strain probiotics for plants, which are formulated to safeguard crops against a wide range of pathogens, including diseases and pests. By utilizing carefully selected beneficial bacteria, Microbe Plus seeks to increase crop yields while minimizing the need for synthetic pesticides. Their mission is to create efficient and cost-effective solutions that support the health of various plants, including crops, orchards, flowers, and ornamental species, thereby contributing to sustainable agricultural practices.

TissueLabs is the platform for creating organs and tissues in the lab. We offer biomaterials, equipment, and services to support tissue engineering and regenerative medicine. Our products are created to allow performing state-of-the-art research, from drug discovery to organ fabrication. Currently, we are focused on attending the academic life sciences market. In the future, our mission is to fabricate lab-grown tissues and organs, for both research and therapeutic applications.

BestHealth4U focuses on the research and development of advanced solutions for manufacturers of class 1 medical devices. The company specializes in medical adhesive technologies that aim to prevent skin injuries, accelerate healing, and enhance overall patient health. Its innovative and environmentally friendly adhesive products are designed to safeguard patients from skin damage, discomfort, irritation, and infections by improving the attachment of bandages, dressings, and medical devices to the skin. By providing effective solutions, BestHealth4U assists healthcare providers in reducing medical adhesive-related skin injuries and promoting the well-being of patients.

Digi.Bio is a Netherlands-based company that specializes in developing software solutions for the healthcare industry, particularly in the field of cell therapies. It offers a microfluidic platform that automates repetitive and manual laboratory workflows, utilizing artificial intelligence and electrowetting technology to manipulate droplets at a microscale. This innovative approach aims to streamline multistep liquid handling applications, replacing traditional pipetting methods. Digi.Bio's platform delivers comprehensive analysis of cell therapies, evaluating their performance and outcomes at the single-cell level within 24 hours, while minimizing material waste. By enhancing automation in medical and pharmaceutical settings, Digi.Bio supports the advancement of bioengineering processes.

Umami Bioworks is a company focused on the discovery and development of a scalable platform for producing cultivated seafood, aiming to protect endangered marine species while providing consumers with sustainable seafood options. The company utilizes systems engineering to enhance the discovery and industrialization processes, facilitating local production that is both price competitive and environmentally responsible. Its innovative approach involves creating cell-based food products derived from fish cells and tissue, which are designed to be free from harmful substances such as mercury, antibiotics, microplastics, and ocean pollutants. By offering affordable, cell-cultured seafood and meat alternatives, Umami Bioworks addresses the growing demand for healthy and sustainable food choices.

MycoNourish specializes in the development of beneficial microbes tailored for specific crops, aiming to enhance agricultural production and add value for growers. By leveraging beneficial fungi that work in symbiosis with various crops, the company improves both yield and quality. MycoNourish focuses on customizing advanced strains of microbes to meet the unique needs of different crops, thereby enabling farmers to cultivate healthier produce. This innovative approach not only supports increased agricultural efficiency but also addresses challenges related to food wastage.

Oxyle AG is a Swiss company based in Zurich that specializes in wastewater treatment aimed at removing persistent and toxic micropollutants from water sources. Established in 2020, the company has developed a novel technology that effectively degrades hazardous substances, including pharmaceuticals, personal-care products, endocrine-disrupting chemicals, pesticides, and industrial chemicals. Oxyle serves a diverse clientele, including the pharmaceutical, biotech, chemical, food and beverage sectors, research laboratories, hospitals, and wastewater treatment facilities. Its innovative approach not only helps clients comply with regulatory standards but also offers a sustainable alternative to wastewater incineration, thereby contributing to reduced CO2 emissions.

Gelatex is a materials technology company based in Estonia, founded in 2016 and incorporated in the UK in 2019. The company has developed a patented technology for producing bio-based nanofibers efficiently and cost-effectively, making it possible to produce these materials at a scale that is significantly faster and cheaper than traditional methods. Gelatex's production process utilizes gelatin derived from low-value waste in the meat and leather industries, ensuring that its products are made from natural and non-toxic substances, which promotes sustainability in the textile sector. Initially focused on creating eco-friendly leather-like textiles, the company pivoted during the COVID-19 pandemic to explore a broader range of applications for its nanofibers, including 3D scaffolds for tissue engineering, cultured meat, bio-based filters, energy storage, and wound care.

ClearLeaf specializes in developing non-toxic fungicides and bactericides for agricultural applications, utilizing patent-pending technology that is organic certified in the EU and Japan. The company offers pre and post-harvest solutions for a variety of crops, including coffee, bananas, pineapples, and various vegetables. Its flagship product, GotaBlanca®, is currently marketed in Costa Rica, with plans to expand into Central America. ClearLeaf has established an exclusive commercial agreement with Colono Agropecuario, the largest agrochemical distributor in the region, which has significantly boosted its sales since the partnership began in 2021. The company's mission is to provide sustainable alternatives to toxic agrochemicals, enhancing farm efficiency while safeguarding human health and the environment, ultimately improving safety conditions for agricultural workers.

Ittinsect is the biotech startup that developed the sustainable alternative to aquaculture feed. Ittinsect produces high performance feeds through the microbiological treatment of novel raw ingredients including insects, microalgae and agricultural by-products, in line with the circular economy principles. With Ittinsect, there is no longer need to catch fish from the marine environment as nutrition for farmed fish. The company’s mission is making aquaculture ocean-impact neutral.

Biotic Circular Technologies specializes in the development and manufacturing of fully bio-based, biodegradable polymers, offering a sustainable alternative to fossil-fuel plastics. The company's end-to-end manufacturing process is designed to eliminate the need for recycling, thus promoting a zero-waste and circular economy. By providing a scalable and environmentally friendly solution, Biotic Circular Technologies aims to address the growing demand for sustainable materials across various applications, including packaging, disposables, and single-use products. Their innovative approach contributes to the reduction of greenhouse gas emissions, aligning with global efforts to transition towards more sustainable practices.

Frankles is a climate technology startup focused on transforming the ingredient production landscape by eliminating petroleum extraction. The company has developed NoDex, an innovative platform that utilizes machine learning and molecular data to design extraction processes from plant raw materials and agro-industrial waste. This technology enables the creation of high-value sustainable ingredients, such as flavorings, functional compounds, antioxidants, and biocompounds. By providing sustainable extraction methodologies, Frankles aims to support the beverage industry in transitioning to green ingredients, contributing to the broader goal of achieving net zero emissions by 2050. Through its scalable solutions, Frankles envisions a decentralized and environmentally friendly approach to ingredient production.

Green and Seed Corporation specializes in innovative rice farming technology. It grows rice outside of water, using biodegradable films that perform weeding and moisture retention, maintaining yields without the need for transplanting or weeding. This method significantly reduces water usage, labor requirements, and greenhouse gas emissions, making it a more sustainable and efficient farming solution.

FermBiotics is a microbiome company dedicated to enhancing gut health globally. The company specializes in the development of sustainable, fermented plant and seaweed ingredients that serve as food components, dietary supplements, and medical foods. By integrating prebiotics, probiotics, and bioactive compounds, FermBiotics has created a novel category of fermented products aimed at promoting a positive gut microbiome. This innovation supports both human and animal health, enabling families and pet owners to assist the elderly and their animals in maintaining optimal gut health.

Michroma Corporation is a biotechnology company that specializes in producing natural thermostable colorants derived from filamentous fungi through a fermentation process. Founded in 2019 and based in both San Francisco, California, and Rosario, Argentina, Michroma aims to replace synthetic pigments and those sourced from animals and plants with sustainable, naturally produced alternatives. The company harnesses synthetic biology to develop proprietary fungal strains that generate high-performance ingredients in bioreactors. Currently, Michroma is prototyping its innovative pH-stable and heat-stable food colorants in collaboration with leading food and beverage and cosmetic companies. Additionally, the company is exploring the production of mycoprotein and other ingredients, making strides in the sustainable ingredients market.